Suppr超能文献

维生素D代谢产物及类似物对大鼠肾脏和肠道钙结合蛋白-D的影响。

Effect of vitamin D metabolites and analogs on renal and intestinal calbindin-D in the rat.

作者信息

Hemmingsen C, Staun M, Lewin E, Nielsen P K, Olgaard K

机构信息

Department of Nephrology P-2131, Rigshospitalet, 9, Blegdamsvej, University of Copenhagen, DK-2100 Copenhagen, Denmark.

出版信息

Calcif Tissue Int. 1996 Nov;59(5):371-6. doi: 10.1007/s002239900142.

Abstract

The effects on renal and intestinal calbindin-D of vitamin D3 metabolites and synthetic 20-epi-vitamin D3 analogs with different calcemic actions were examined in Wistar rats. The compounds were administered intraperitoneally once daily for 5 days. The dosages of the metabolites were 1,25-(OH)2D3 0.01, 0.05, 0.1, and 0.4 microg/kg x d, 24,25-(OH)2D3 0.1, 1 and 10 microg/kg x d, and 25-(OH)D3 10 and 400 microg/kg x d. The dosage of the synthetic analogs were MC903 0. 1, 10, and 100 microg/kg x d, EB1213 0.1 and 10 microg/kg x d, KH1060 0.1 and 0.4 microg/kg x d, and GS1725 0.01 and 0.1 microg/kg x d. Two control groups had either vehicle alone or no treatment. N = 8 in each group. 1,25-(OH)2D3 increased renal and intestinal calbindin-D levels, induced hypercalcemia, and suppressed plasma PTH and magnesium concentrations. 24,25-(OH)2D3 increased intestinal calbindin-D9k and plasma calcium, but had no effect on renal calbindin-D28k, plasma PTH, and magnesium. The dosage of 24, 25-(OH)2D3 that was required to increase plasma calcium was larger than the dosage required to increase intestinal calbindin-D9k. 25-(OH)D3 did not change the calcium metabolic parameters. MC903, a low calcemic analog with a relative high affinity for the vitamin D receptor and a short half-life, increased renal calbindin-D28k without increasing ionized calcium or intestinal calbindin-D9k. EB1213, an analog with a reduced calcemic action and short half-life, increased renal calbindin-D28k and ionized calcium without increasing intestinal calbindin-D9k. The effect of the high calcemic vitamin D analogs KH1060 and GS1725 on calbindin-D was directly related to their calcemic activity. In conclusion, these results demonstrate that 24,25-(OH)2D3 increases intestinal calbindin-D9k, but has no effect on renal calbindin-D28k, that low calcemic analogs may increase renal calbindin-D28k without increasing intestinal calbindin-D9k, and that the effect of high calcemic analogs on calbindin-D is directly related to their calcemic activity.

摘要

在Wistar大鼠中研究了具有不同血钙调节作用的维生素D3代谢物和合成的20-表维生素D3类似物对肾脏和肠道钙结合蛋白-D的影响。化合物每日腹腔注射一次,共5天。代谢物的剂量分别为1,25-(OH)2D3 0.01、0.05、0.1和0.4μg/kg×d,24,25-(OH)2D3 0.1、1和10μg/kg×d,以及25-(OH)D3 10和400μg/kg×d。合成类似物的剂量分别为MC903 0.1、10和100μg/kg×d,EB1213 0.1和10μg/kg×d,KH1060 0.1和0.4μg/kg×d,以及GS1725 0.01和0.1μg/kg×d。两个对照组分别单独给予赋形剂或不进行处理。每组n = 8。1,25-(OH)2D3增加肾脏和肠道钙结合蛋白-D水平,诱发高钙血症,并抑制血浆甲状旁腺激素(PTH)和镁浓度。24,25-(OH)2D3增加肠道钙结合蛋白-D9k和血浆钙,但对肾脏钙结合蛋白-D28k、血浆PTH和镁无影响。增加血浆钙所需的24,25-(OH)2D3剂量大于增加肠道钙结合蛋白-D9k所需的剂量。25-(OH)D3未改变钙代谢参数。MC903是一种对维生素D受体具有相对高亲和力且半衰期短的低血钙类似物,可增加肾脏钙结合蛋白-D28k,而不增加离子钙或肠道钙结合蛋白-D9k。EB1213是一种血钙调节作用减弱且半衰期短的类似物,可增加肾脏钙结合蛋白-D28k和离子钙,而不增加肠道钙结合蛋白-D9k。高血钙维生素D类似物KH1060和GS1725对钙结合蛋白-D的作用与其血钙调节活性直接相关。总之,这些结果表明,24,25-(OH)2D3增加肠道钙结合蛋白-D9k,但对肾脏钙结合蛋白-D28k无影响;低血钙类似物可能增加肾脏钙结合蛋白-D28k而不增加肠道钙结合蛋白-D9k;高血钙类似物对钙结合蛋白-D的作用与其血钙调节活性直接相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验